论文部分内容阅读
对20例经手术切除的进展期肿瘤患者用活化的肿瘤浸润淋巴细胞（TIL）和重组人白细胞介素-2（rhIL－2）治疗，检测治疗前后细胞免疫功能变化。其中8例治疗后PBL对同种异体相同组织学类型靶细胞的细胞毒性从43．2升高到1249．0溶解单位（P＜0．05），而NK活性无明显变化；T4、T8淋巴细胞亚群荧光强度明显升高，从1．9到3．9（P＜0．05）及4．4到7．2（P＜0．05）。所有患者PPD及PHA反应性明显增强，从10．9mm到13．6mm（P＜0．01）及7．9mm到12．7mm（P＜0．01），15例有一过性寒战、发热，其中10例伴轻度恶心、呕吐。结果提示：TIL和rhIL－2治疗后可明显提高进展期肿瘤患者的细胞免疫功能，而无明显毒副作用，可能成为进展期肿瘤术后重要的辅助治疗方法。
Twenty patients with advanced tumors undergoing surgical resection were treated with activated tumor-infiltrating lymphocytes (TIL) and recombinant human interleukin-2 (rhIL-2) to detect changes in cellular immune function before and after treatment. The cytotoxicity of PBL on the same histological type of target cells after treatment was increased from 43.2 to 1249.0 lysis units (P<0.05), and there was no significant change in NK activity; T4, T8 lymph The fluorescence intensity of the cell subpopulation increased significantly from 1.9 to 3.9 (P<0.05) and 4.4 to 7.2 (P<0.05). All patients had significantly increased PPD and PHA reactivity from 10.9mm to 13.6mm (P<0.01) and 7.9mm to 12.7mm (P<0.01). 15 patients had transient chills and fever. Ten of them had mild nausea and vomiting. The results suggest that TIL and rhIL-2 can significantly improve the cellular immune function of patients with advanced tumors without significant side effects, and may become an important adjuvant treatment after advanced tumor surgery.